Relay Therapeutics (RLAY) to Release Earnings on Tuesday

Key Points

• Relay Therapeutics (NASDAQ: RLAY) is set to announce its Q2 2025 earnings on August 5th, with analysts anticipating earnings of ($0.49) per share and revenue of $0.07 million.
• In the last earnings report, Relay Therapeutics reported earnings of ($0.46) per share and revenue of $7.68 million, surpassing estimates by a significant margin.
• The stock has seen a 1.1% decline recently and has a market cap of approximately $634.35 million, reflecting its current position in the market.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 5th. Analysts expect Relay Therapeutics to post earnings of ($0.49) per share and revenue of $0.07 million for the quarter.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.04. The firm had revenue of $7.68 million during the quarter, compared to analyst estimates of $0.01 million. During the same period in the previous year, the company earned ($0.62) earnings per share. Relay Therapeutics's revenue was down 23.0% on a year-over-year basis. On average, analysts expect Relay Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Relay Therapeutics Stock Performance

Shares of NASDAQ RLAY traded down $0.16 during mid-day trading on Friday, hitting $3.36. The stock had a trading volume of 2,789,533 shares, compared to its average volume of 2,326,052. The company has a 50 day moving average of $3.41 and a two-hundred day moving average of $3.40. Relay Therapeutics has a twelve month low of $1.77 and a twelve month high of $10.72. The firm has a market cap of $576.06 million, a PE ratio of -1.51 and a beta of 1.62.

Analysts Set New Price Targets

RLAY has been the topic of several analyst reports. Guggenheim cut their price target on Relay Therapeutics from $30.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Wells Fargo & Company initiated coverage on Relay Therapeutics in a research report on Thursday, April 17th. They set an "equal weight" rating and a $4.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $17.67.

Insider Buying and Selling at Relay Therapeutics

In other news, CFO Thomas Catinazzo sold 18,380 shares of the stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $3.68, for a total transaction of $67,638.40. Following the sale, the chief financial officer directly owned 335,295 shares of the company's stock, valued at $1,233,885.60. This represents a 5.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Sanjiv Patel sold 61,379 shares of the stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $3.57, for a total transaction of $219,123.03. Following the sale, the chief executive officer directly owned 765,288 shares in the company, valued at approximately $2,732,078.16. The trade was a 7.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 149,226 shares of company stock worth $542,926. 4.87% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Relay Therapeutics

Several hedge funds have recently modified their holdings of the company. Dynamic Technology Lab Private Ltd purchased a new position in Relay Therapeutics in the 1st quarter valued at about $53,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Relay Therapeutics by 6.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,069 shares of the company's stock valued at $221,000 after buying an additional 5,238 shares in the last quarter. Jane Street Group LLC lifted its stake in Relay Therapeutics by 47.6% in the 1st quarter. Jane Street Group LLC now owns 111,472 shares of the company's stock valued at $292,000 after buying an additional 35,962 shares in the last quarter. AQR Capital Management LLC lifted its stake in Relay Therapeutics by 11.9% in the 1st quarter. AQR Capital Management LLC now owns 364,946 shares of the company's stock valued at $956,000 after buying an additional 38,812 shares in the last quarter. Finally, Woodline Partners LP lifted its stake in Relay Therapeutics by 448.4% in the 1st quarter. Woodline Partners LP now owns 1,518,561 shares of the company's stock valued at $3,979,000 after buying an additional 1,241,657 shares in the last quarter. 96.98% of the stock is owned by hedge funds and other institutional investors.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.